Published in Blood Weekly, February 12th, 2004
UCB "is now being considered an alternative to bone marrow for restoring hematopoiesis after myeloablative therapy," scientists in Spain noted. "The lower risk of acute and chronic graft-versus-host disease in patients who received UCB cells seems related to the nature of UCB-T cells."
"Phenotypically, UCB-CD3+ cells are mostly naive (CD45RA+) and represent a transitional population between thymocytes and adult T cells," explained E. Canto and colleagues at Sant Pau Hospital in Barcelona, who "examined the immune reactivity of highly purified, negatively selected...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.